Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy

Triple-negative breast cancer (TNBC) patients who do not achieve pathologic complete response post neoadjuvant chemotherapy have a poor prognosis. Alteration in PI3K/mTOR plus DNA repair pathways are some of the major mechanisms of chemotherapy resistance. We designed an open-label phase II clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Kartik, Patel, Tejal, Niravath, Polly, Rodriguez, Angel, Darcourt, Jorge, Belcheva, Anna, Boone, Toniva, Ensor, Joe, Chang, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794349/
https://www.ncbi.nlm.nih.gov/pubmed/33420229
http://dx.doi.org/10.1038/s41598-020-80081-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794349/
https://www.ncbi.nlm.nih.gov/pubmed/33420229
http://dx.doi.org/10.1038/s41598-020-80081-y

Ejemplares similares